(Q42201268)

English

Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial

scientific article published on 4 August 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

anti-retroviral agent

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Clotilde Allavena

14

object named as

Clotilde Allavena

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Geneviève Chêne

18

object named as

Geneviève Chêne

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Jean-François Delfraissy

16

object named as

Jean-François Delfraissy

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Elizabeth C George

object named as

Elizabeth C George

5

0 references

Jose R. Arribas

object named as

Jose R Arribas

7

0 references

object named as

Stefano Vella

17

0 references

Andrea Antinori

6

object named as

Andrea Antinori

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Jean-Michel Molina

4

object named as

Jean-Michel Molina

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

François Raffi

1

object named as

François Raffi

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

author name string

Abdel G Babiker

2

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Laura Richert

3

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Jesper Grarup

8

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Fleur Hudson

9

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Christine Schwimmer

10

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Juliette Saillard

11

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Cédrick Wallet

12

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Per O Jansson

13

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Remko Van Leeuwen

15

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Anton Pozniak

19

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

NEAT001/ANRS143 Study Group

20

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

language of work or name

0 references

publication date

4 August 2014

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

384

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

9958

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

1942-1951

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961170-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Bone disease in HIV infection: a practical review and recommendations for HIV care providers

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961170-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naïve patients in the ARTEMIS trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961170-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961170-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961170-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Plasma and intracellular pharmacokinetics of darunavir/ritonavir once daily and raltegravir once and twice daily in HIV-infected individuals

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961170-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961170-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Prediction of creatinine clearance from serum creatinine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961170-3

7 January 2021

based on heuristic

inferred from DOI database lookup

When to stop a clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961170-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961170-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961170-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Class-sparing regimens for initial treatment of HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961170-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Lopinavir/ritonavir combined with raltegravir or tenofovir/emtricitabine in antiretroviral-naive subjects: 96-week results of the PROGRESS study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961170-3

7 January 2021

based on heuristic

inferred from DOI database lookup

A nucleoside- and ritonavir-sparing regimen containing atazanavir plus raltegravir in antiretroviral treatment-naïve HIV-infected patients: SPARTAN study results

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961170-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961170-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961170-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961170-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961170-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Antiretroviral treatment of HIV-1 prevents transmission of HIV-1: where do we go from here?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961170-3

7 January 2021

based on heuristic

inferred from DOI database lookup

In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961170-3

7 January 2021

based on heuristic

inferred from DOI database lookup

All-cause mortality in treated HIV-infected adults with CD4 ≥500/mm3 compared with the general population: evidence from a large European observational cohort collaboration

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961170-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961170-3

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: analysis of week 96 resul

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961170-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Lower pill burden and once-daily antiretroviral treatment regimens for HIV infection: A meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961170-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Pragmatic trials--guides to better patient care?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961170-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Methodological issues in the use of composite endpoints in clinical trials: examples from the HIV field

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961170-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Design of HIV noninferiority trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961170-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(14)61170-3

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42201268&oldid=1986236009"